

Toxoplasmosis

Selected References:

- Alvarado-Esquivel C, et al. 2015. High seroprevalence of *Toxoplasma gondii* infection in female sex workers: A case-control study. *Eur J Microbiol (Bp)*; 5(4):285-292.
- Abdoloe A, et al. 2012. Impaired reproductive function of male rats infected with *Toxoplasma gondii*. *Andrologia*; 44 Suppl 1:679-687.
- Arce-Estrada GE, et al. 2017. Report of an unusual case of anophthalmia and craniofacial cleft in a newborn with *Toxoplasma gondii* congenital infection. *BMC Infect Dis*; 17(1):459.
- Assistant Secretary for Public Affairs (ASPA). 2022. Cook to a safe minimum internal temperature. FoodSafety.gov. <https://www.foodsafety.gov/food-safety-charts/safe-minimum-internal-temperatures>.
- Bonetti A, et al. 2025. Risk of Congenital Toxoplasmosis in Newborns from Mothers with Documented Infection: Experience from Two Referral Centres. *Pathogens*; 14(2):157.
- Buonsenso D, et al. 2022. Spyramicine and Trimethoprim-Sulfamethoxazole Combination to Prevent Mother-To-Fetus Transmission of *Toxoplasma gondii* Infection in Pregnant Women: A 28-Years Single-center Experience. *Pediatr Infect Dis J*; 41(5).
- Cerisola A, et al. 2025. Congenital toxoplasmosis. *Semin Pediatr Neurol*; 54:101203.
- Codaccioni C, et al. 202. Ultrasound features of fetal toxoplasmosis: A contemporary multicenter survey in 88 fetuses. *Prenat Diagn*; 40(13):1741-1752.
- Cook AJC, et al. 2000. Sources of toxoplasmosis in pregnant women. *BMJ*; 321:142-147.
- Conceição AR, et al. 2021. Ocular Findings in Infants with Congenital Toxoplasmosis after a Toxoplasmosis Outbreak. *Ophthalmology*; 128(9):1346-1355.
- Cortina-Borja M, et al, & European Multicentre Study on Congenital Toxoplasmosis (EMSCOT). 2010. Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: an observational prospective cohort study. *PLoS Med*; 7(10):e1000351.
- Couvreur J, et al. 1993. In utero treatment of toxoplasmic fetopathy with the combination pyrimethamine-sulfadiazine. *Fetal Diagn Ther*; 8:45-50.
- Dadoun S, et al. 2024. Congenital toxoplasmosis of the brain caused by infection in late pregnancy. *Lancet*; 403(10431):1081-1082.
- Daffos F, et al. 1988. Prenatal management of 746 pregnancies at risk for congenital toxoplasmosis. *N Engl J Med*; 318(5):271-275.
- Damar Çakırca T, et al. 2023. Toxoplasmosis: A Timeless Challenge for Pregnancy. *Trop Med Infect Dis*; 8(1):63.
- Dard C, et al. 2017. Late diagnosis of congenital toxoplasmosis based on serological follow-up: A case report. *Parasitol Int*; 66(2):186-189.
- D'Ercole C, et al. 1995. Recurrent congenital toxoplasmosis in a woman with lupus erythematosus. *Prenat Diagn*; 15(12):1171-1175.
- Desmonts G, Couvreur J. 1974. Congenital toxoplasmosis. A prospective study of 378 pregnancies. *N Engl J Med*; 290(20):1110-6.
- Dhombres F, et al. 2017. Prognosis of fetal parenchymal cerebral lesions without ventriculomegaly in congenital toxoplasmosis infection. *Fetal Diagn Ther*; 41(1):8-14.
- Dubey JP and Jones JL. 2008. *Toxoplasma gondii* infection in humans and animals in the United States. *Int J Parasitol*; 38:1257-1278.
- Ducrot SB, et al. 2018. Neonatal fever: A puzzling case. *Arch Pediatr*; 25(7):435-438.
- Dunn D, et al. 1999. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counseling. *Lancet*; 353:1829-1833.
- El-Beshbishi SN, et al. 2025. The Impact of Chronic Toxoplasmosis on the Gonadotropic Gonadal Axis in Male

Rats. *Acta Parasitol*; 71(1):3.

- Elbez-Rubinstein A, et al. Congenital toxoplasmosis and reinfection during pregnancy: case report, strain characterization, experimental model of reinfection, and review. *J Infect Dis*; 199(2):280-5.
- Fallahi S, et al. 2018. An updated literature review on maternal-fetal and reproductive disorders of *Toxoplasma gondii* infection. *Gynecol Obstet Hum Reprod*; 47(3):133-140.
- Feldman DM, et al. 2016. Toxoplasmosis, parvovirus, and cytomegalovirus in pregnancy. *Clin Lab Med*; 36(2):407-419.
- Ferreira L, et al. 2024. Congenital toxoplasmosis and auditory disorders: a literature review. *Front Psychol*; 14:1286211.
- Flegr J, et al. 2014. Toxoplasmosis can be a sexually transmitted infection with serious clinical consequences. Not all routes of infection are created equal. *Med Hypotheses*; 83(3):286-289.
- Foulton W, et al. 1999. Prenatal diagnosis of congenital toxoplasmosis: a multicenter evaluation of different diagnostic parameters. *Am J Obstet Gynecol*; 181(4):843-847.
- Foulton W, et al. 1999. Treatment of toxoplasmosis during pregnancy: a multicenter study of impact on fetal transmission and children's sequelae at age 1 year. *Am J Obstet Gynecol*; 180(2):410-415.
- Gilbert RE, Stanford MR. 2000. Is ocular toxoplasmosis caused by prenatal or postnatal infection. *Br J Ophthalmol*; 84(2):224-226.
- Giugno S, et al. 2020. Congenital toxoplasmotic chorioretinitis following reinfection. *Eur J Obstet Gynecol Reprod Biol*; 251:263-265.
- Groer MW, et al. 2011. Prenatal depression and anxiety in *Toxoplasma gondii* positive women. *Am J Obstet Gynecol*; 204(5):433.e1-7.
- Guerina NG, et al. 1994. Neonatal serologic screening and early treatment for congenital *Toxoplasma gondii* infection. The New England Regional *Toxoplasma* Working Group. *N Engl J Med*; 330(26):1858-63.
- Gundeslioglu OO, et al. 2024. Congenital Toxoplasmosis and Long-term Outcomes. *Turkiye Parazitol Derg*; 48(1):8-14.
- Gunturiz ML, et al. 2018. Congenital cerebral toxoplasmosis, Zika, and chikungunya virus infections: a case report. *Biomedica*; 38(2):144-152.
- Hampton MM. 2015. Congenital toxoplasmosis: A review. *Neonatal Netw*; 34(5):274-278.
- Hide G, et al. 2009. Evidence for high levels of vertical transmission in *Toxoplasma gondii*. *Parasitol*; 136:1877-1885.
- Hlaváčová J, et al. 2021. Male-to-female presumed transmission of toxoplasmosis between sexual partners. *Am J Epidemiol*; 190(3):386-392.
- Hlaváčová, Jet al. 2021, Association between latent toxoplasmosis and fertility parameters of men. *Andrology*; 9: 854-862.
- Hohlfeld P, et al. 1991. Fetal toxoplasmosis: ultrasonographic signs. *Ultrasound Obstet Gynecol*; 1(4):241-4.
- Hohlfeld P, et al. 1994. Prenatal diagnosis of congenital toxoplasmosis with a polymerase-chain-reaction test on amniotic fluid. *N Engl J Med*; 331(11):695-699.
- Hosseini SA, et al. 2025. Latent toxoplasmosis and preeclampsia: evidence for the role of chronic infection in pregnancy complications. *BMC Pregnancy Childbirth*; 25(1):1130.
- Hunter K, et al. 1983. Prenatal screening of pregnant women for infections caused by cytomegalovirus, Epstein-Barr virus, herpesvirus, rubella, and *Toxoplasma gondii*. *Am J Obstet Gynecol*; 145:269-273.
- Hurt K, et al. 2022. Toxoplasmosis impact on prematurity and low birth weight. *PLoS One*; 17(1).
- Jones, CA. 2001. Maternal transmission of infectious pathogens in breast milk. *J Paediatr Child Health*; 37:576-582.
- Jones JL et al. 2001. Toxoplasmosis *gondii* infection in the United States: Seroprevalence and Risk Factors. *Am J Epidemiol*; 4:357-365.
- Kahn K, Kahn W. 2018. Congenital toxoplasmosis: An overview of the neurological and ocular manifestations. *Parasitol Int*; (67(6):715-721.

- Kalantari N, et al. 2021. Toxoplasma gondii infection and spontaneous abortion: A systematic review and meta-analysis. *Microb Pathog*; 158:105070.
- Kaňková Š, et al. 2015. The influence of latent toxoplasmosis on women's reproductive functions: four cross-sectional studies. *Folia Parasitol (Praha)*; 62:2015.041.
- Kaňková Š, et al. 2020. Oral sex: A new, and possibly the most dangerous, route of toxoplasmosis transmission. *Med Hypotheses*; 141:109725.
- Kazemi F, et al. 2023. Toxoplasma and Risk of Spontaneous Abortion: A Meta-Analysis in A Population of Iranian Women. *Int J Fertil Steril*; 17(1):7-11.
- Khamsian EM, et al. 2021. Toxoplasma gondii in milk of human and goat from the desert area in Central Iran. *Iran J Parasitol*; 16(4): 601-609.
- Koppe JG, et al. 1986. Results of 20-year follow-up of congenital toxoplasmosis. *Lancet*; 1:254-255.
- Li XL, et al. 2014. A meta analysis on risks of adverse pregnancy outcomes in Toxoplasma gondii infection. *PLoS One*; 9(5):e97775.
- Lopez A, et al. 2000. Preventing congenital toxoplasmosis. *MMWR Recomm Rep*; 49(RR-2):59-68.
- Lynfield R and Eaton RB. 1995. Teratogen update: Congenital toxoplasmosis. *Teratology*; 52(3):176-180.
- Maldonado YA, Read JS; Committee on Infections Diseases. 2017. Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States. *Pediatrics*; 139(2):e20163860.
- Malinger G, et al, 2011. Herrera M. Prenatal brain imaging in congenital toxoplasmosis. *Prenat Diagn*; 31(9):881-6.
- Marsolkova K, et al. 2018. Congenital central toxoplasmosis chorioretinitis – case study. *Cesk Slov Oftalmol*; 74(3):114-118.
- Martinez VO, et al. 2023. Impact of chronic toxoplasmosis in pregnancy: association between maternal seropositivity for Toxoplasma gondii IgG antibodies and fetal growth restriction. *Parasitol Res*; 123(1):25.
- Matini M, et al. 2026. Toxoplasmosis: sperm parameters and testosterone levels in men. *J Parasit Dis*; 50(1):244-249.
- Matsui D. 1994. Prevention, diagnosis and treatment of fetal toxoplasmosis. *Clin Perinatol*; 21(3):675-689.
- Merz E. 2004. Ultrasound in obstetrics and gynecology. Vol. 1: obstetrics. 2nd ed. New York, NY: Thieme.
- McLeod R, et al. 2014. Management of congenital toxoplasmosis. *Curr Pediatr Rep*; 2:166-194.
- Montoya JG, Liesenfeld O. 2004 Toxoplasmosis. *Lancet*. 363(9425):1965-1976.
- Montoya JC & Remington JS. 2008. Management of Toxoplasma gondii infection during pregnancy. *Clin Infect Dis*; 47(4):554-566.
- National Center for Infectious Diseases and the CDC. 2000. Preventing Congenital Toxoplasmosis. *MMWR*. 49(RR02);57-75.
- Njoh AA, et al. 2016. Fetal malformation in maternal toxoplasma and rubella co-infection in Cameroon: A case report. *J Med Case Rep*; 10(1):345.
- Nourollahpour Shiadeh M, et al. 2020. The prevalence of latent and acute toxoplasmosis in HIV-infected pregnant women: A systematic review and meta-analysis. *Microb Pathog*; 149:104549.
- Orevaoghene OE, et al. 2025. Evaluation of Maternal and Neonatal Risk Factors in the Transmission of Toxoplasmosis: A Study on the Detection of Toxoplasma gondii Antibodies in Cord Blood. *Ethiop J Health Sci*. 2025 Jul;35(4):267-273.
- Oz HS. 2017. Fetomaternal and pediatric toxoplasmosis. *J Pediatr Infect Dis*; 12(4): 202-208.
- Paquet C, Yudin MH; Society of Obstetricians and Gynaecologists of Canada. 2013. Toxoplasmosis in pregnancy: prevention, screening, and treatment. *J Obstet Gynaecol Can*; 35(1):78-81.
- Paquet C, Yudin MH. 2018. No. 285-Toxoplasmosis in pregnancy: Prevention, screening, and treatment. *J Obstet Gynaecol Can*; 40(8):e687-e693.
- Picone O, et al. 2020. Toxoplasmosis screening during pregnancy in France: Opinion of an expert panel for the CNGOF. *J Gynecol Obstet Hum Reprod*; 49(7):101814.
- Prusa A-R, et al. 2015. The Austrian toxoplasmosis register, 1992-2008. *Clin Infect Dis*; 60(2): e4-e10.

- Rajapakse S, et al. 2017. Prophylaxis of human toxoplasmosis: a systematic review. *Pathog Glob Health*; 111(7):333-342.
- Red Book: 2024–2027. Report of the Committee on Infectious Diseases (33rd Edition). *Toxoplasma gondii* Infections (Toxoplasmosis). Red book (Elk Grove Village, Ill.), p.867.
- Rehman F, et al. 2020. Unpasteurized milk consumption as a potential risk factor for toxoplasmosis in females with recurrent pregnancy loss. *J Obstet Gynaecol*; 4:1-5.
- Rico-Torres CP, et al. 2016. Is *Toxoplasma gondii* type related to clinical outcome in human congenital infection? Systematic and critical review. *Eur J Clin Microbiol Infect Dis*; 35(7):1079-1088.
- Robert-Gangneux F, Darde M-L. 2012. Epidemiology of and diagnostic strategies for toxoplasmosis. *Clin Microbiol Rev*; 25(2) :264-296.
- Rojas-Barón L, et al. 2025. Adverse impact of acute *Toxoplasma gondii* infection on human spermatozoa. *FEBS J*; 292(17):4720-4736.
- Sanders AP, et al. 2017. Ocular lesions in congenital toxoplasmosis in Santa Isabel do Ivaí, Paraná, Brazil. *Pediatr Infect Dis J*; 36(9):817-820.
- Shojaee S, et al. 2018. The relation of secondary sex ratio and miscarriage history with *Toxoplasma gondii* infection. *BMC Infect Dis*; 18(1):307.
- Simon L, et al. 2020. A case of toxoplasmosis-associated miscarriage with maternal infections four months prior to conception. *Parasitol Int*; 79:102165.
- Smit GSA, et al. 2017. Public health impact of congenital toxoplasmosis and cytomegalovirus infection in Belgium, 2013: a systematic review and data synthesis. *Clin Infect Dis*; 65(4):661-668.
- Spann MN, et al. 2017. Prenatal toxoplasmosis antibody and childhood autism. *Autism Res*; 10(5):769-777.
- Stray-Pedersen B. 1993. Toxoplasmosis in pregnancy. *Baillieres Clin Ob Gynecol*; 7(1):107-137.
- Tamma P. 2007. Toxoplasmosis. *Pediatr Rev*; 28(12):470-1.
- Torrey EF, et al. 2012. Toxoplasmosis *gondii* and other risk factors for schizophrenia: an update. *Schizophr Bull*; 38(3):642-647.
- The American College of Obstetricians and Gynecologists (ACOG). 2015, reaffirmed 2024. Practice bulletin # 151: Cytomegalovirus, Parvovirus B19, Varicella Zoster, and Toxoplasmosis in Pregnancy. *Ob Gyn* 125(6): 1510-1525.
- The Centers for Disease Control and Prevention (CDC):About Toxoplasmosis. 2025. Available at: <https://www.cdc.gov/toxoplasmosis/about/index.html>. [Accessed 3/31/26]. Clinical Overview of Toxoplasmosis. 2024. Available at: <https://www.cdc.gov/toxoplasmosis/hcp/clinical-overview/index.html>. [Accessed 3/31/26].
- Toxoplasmosis and Breastfeeding. 2025. Available at: <https://www.cdc.gov/breastfeeding-special-circumstances/hcp/illnesses-conditions/toxoplasmosis.html>. [Accessed 3/31/26].
- The Toxoplasmosis Study Group. 1990. Congenital toxoplasmosis. *Am J Dis Child*; 144:619.
- Túzkó N, et al. 2024. Associations between Fetal Symptoms during Pregnancy and Neonatal Clinical Complications with Toxoplasmosis. *Children (Basel)*; 11(9):1111.
- Villena I, et al. 1998. Prenatal diagnosis of congenital toxoplasmosis transmitted by an immunocompetent woman infected before conception. Reims Toxoplasmosis Group. *Prenat Diagn*; 18(10):1079-81.
- Walana W, et al. 2026. Prevalence, risk factors, diagnosis and outcomes of *Toxoplasma gondii* infection in pregnancy: A review. *Parasitol Int*; 110:103143.
- Wallon M, et al. 2014. Ophthalmic outcomes of congenital toxoplasmosis followed until adolescence. *Pediatrics*; 133(3):e601-8.
- Wallon M, Peyron F. 2018. Congenital toxoplasmosis: A plea for a neglected disease. *Pathogens*; 7(1):25.
- Werner H, et al. 2017. Neuroimaging findings of congenital toxoplasmosis, cytomegalovirus, and Zika virus infections: A comparison of three cases. *J Obstet Gynaecol Can*; 39(12):1150-1155.
- Wilson CB. 1980. Development of adverse sequelae in children born with subclinical toxoplasmosis infection. *Pediatrics*; 66(5):767-774.

- Zhang F, et al. 2024. Toxoplasma gondii Causes Adverse Pregnancy Outcomes by Damaging Uterine Tissue-Resident NK Cells That Secrete Growth-Promoting Factors. J Infect Dis; 229(2):547-557.
- Zhao F, et al. 2026. Clinical characteristics and associated risk factors for diminished ovarian reserve among Chinese women: a matched case-control study. Front Endocrinol (Lausanne); 17:1767835.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de abril de 2026.

Toxoplasmosis

Selected References:

- Bang Madsen K, et al. 2023. In utero exposure to ADHD medication and long-term offspring outcomes. Molecular psychiatry; 28(4):1739–1746.
- Boutroy MJ, et al. 1988. Clonidine: Placental transfer and neonatal adaption. Early Hum Dev; 17:275-286.
- Bunjes R, Schaefer C. 1993. Clonidine and breast-feeding. Clinical Pharm 12:178-9.
- Frazier, LM, et al. 2020. Emerging therapies for the treatment of neonatal abstinence syndrome. The Journal of Maternal-Fetal & Neonatal Medicine; 6:1-9.
- Horvath JS, et al. 1985. Clonidine hydrochloride a safe and effective antihypertensive agent in pregnancy. Obstet Gynecol; 66:634-8.
- Huisjes, et al. 1986. Is clonidine a behavioural teratogen in the human? Early Hum Dev; 14:43-8.
- Khan A, et al. 1970. Clonidine (Catapres): a new anti-hypertensive agent. Cur Ther Res; 12:10.
- Liu X, et al. 2026. Clonidine compromises human sperm functions. Reproductive Toxicology; 140, 109164.
- Maina A, et al. 2014. Transdermal clonidine in the treatment of severe hyperemesis: A pilot randomized controlled trial (CLONEMESI). BJOG: An International Journal of Obstetrics & Gynaecology; 121,1556–1562.
- Mirmiran M. 1986. The importance of fetal/neonatal REM sleep. Eur J Obstet Gynecol Reprod Biol; 21:283-91.
- Rothberger S, et al. 2010. Pharmacodynamics of clonidine therapy in pregnancy: a heterogeneous maternal response impacts fetal growth. Am J Hypertens; 23(11):1234-40.

- Sevez C, et al. 2014. [Transplacental or breast milk intoxication to clonidine: a case of neonatal hypotonia and drowsiness]. Arch Pediatr; 21(2):198-200.
- Stoll C, et al. 1979. Robert's syndrome and clonidine. J Med Genet; 16:486-8.
- Terada H, et al. 2005. Oral clonidine advances spermatogenesis in oligozoospermic patients with spermatogenetic maturation arrest. International journal of urology: official journal of the Japanese Urological Association; 12(9),815-820.
- Tuimala R, et al. 1985. Clonidine in the treatment of hypertension during pregnancy. Annales Chirurgiae et Gynaecologiae Supplementum; 197,47-50.
- Tsai TH, et al. 1982. Teratologic and reproductive studies of lofexidine. Arzneimittelforsch; 32:962-6.
- Zangeneh F, et al. 2022. The first report of clonidine in vivo/in vitro effects on infertile women with polycystic ovary syndrome (in vivo/in vitro study). Journal of the Institute of Obstetrics and Gynaecology; 42(5),1331-1339.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de abril de 2026.

Toxoplasmosis

Selected References:

- Allocca M, et al. 2018. Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men. Eur J Gastroenterol Hepatol. 30(3):316-322.
- Asthana R, et al. 2025. Meta-analysis and systematic review on sulfasalazine/5-ASA use during pregnancy: Impact on neonatal and pregnancy outcomes. Reprod Toxicol 135:108939.
- Ban L et al. 2014. Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications. Gastroenterology. 146 (1):76-84. Banerjee, A et al. 2019. Inflammatory
- Bowel Disease Therapies Adversely Affect Fertility in Men- A Systematic Review and Meta-analysis. Endocrine, metabolic & immune disorders drug targets, 19(7), 959-974.
- Chermesh I & Eliakim R. 2004. Mesalazine-induced reversible infertility in a young male. Dig Liver Dis 36:551-2.

- Diav-Citrin O, et al. 1998. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. *Gastroenterology*; 114:23-28.
- Gaidos J. & Kane SV. 2020. Medication Adherence During Pregnancy in IBD: Compliance Avoids Complications. *Digestive diseases and sciences*, 10.1007/s10620-020-06271-w. Advance online publication.
- Hosseini-Carroll P, et al. 2015. Pregnancy and inflammatory bowel diseases: Current perspectives, risks and patient management. *World J Gastrointest Pharmacol Ther*. 6(4):156-171.
- Ito S, et al. 1993. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. *Am J Obstet Gynecol*. 168:1393-9.
- Källén B. 2014. Maternal use of 5-aminosalicylates in early pregnancy and congenital malformation risk in the offspring. *Scand J Gastroenterol*; 49(4):442-8.
- Mahadevan U, Matro R. Care of the pregnant patient with inflammatory bowel disease. *Obstet Gynecol*. 2015;126:401-12.
- Maliszewska, AM, et al. 2017. Inflammatory bowel disease and pregnancy. *Ginekologia Polska*, 88(7), 398-403.
- Marteau P & Devaux CB. 1994. Mesalazine during pregnancy. *Lancet* 344(8938):1708-1709.
- Moskovitz DN, et al. 2004. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. *Am J Gastroenterol* 99(4):656-661.
- Moretti ME. 1998. Prospective follow-up of infants exposed to 5-aminosalicylic acid containing drugs through maternal milk. *Theses Canada*. Moretti ME, et al. 1998. Prospective follow-up of infants exposed to 5-aminosalicylic acid containing drugs through maternal milk. *J Clin Pharmacol*. 38:867.
- Nelis GF. 1989. Diarrhoea due to 5-aminosalicylic acid in breastmilk. *Lancet* 1:383.
- Nielsen OH, et al. 2014. IBD medications during pregnancy and lactation. *Nat Rev Gastroenterol Hepatol*. 11(2):116-127.
- Norgård, B et al. 2003. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. *Gut*, 52(2), 243-247.
- Pervez, H, et al. 2019. The Impact of Inflammatory Bowel Disease on Pregnancy and the Fetus: A Literature Review. *Cureus*, 11(9), e5648.
- Shin T, et al. 2014. Inflammatory bowel disease in subfertile men and the effect of mesalazine on fertility. *Syst Biol Reprod Med*. 60(6); 373-376.
- Silverman DA, et al. 2005. Is mesalazine really safe for use in breastfeeding mothers? *Gut* 54: 170-1.
- Watanabe, C. et al. 2020. Non-adherence to Medications in Pregnant Ulcerative Colitis Patients Contributes to Disease Flares and Adverse Pregnancy Outcomes. *Digestive diseases and sciences*, 10.1007/s10620-020-06221-6. Advance online publication.
- Wiersma TK, et al. 2022. The Effect of Pregnancy and Inflammatory Bowel Disease on the Pharmacokinetics of Drugs Related to Inflammatory Bowel Disease-A Systematic Literature Review. *Pharmaceutics*. 14(6):1241.
- Xu YL, et al. 2017. Inflammatory bowel disease in pregnancy: A report of 7 cases and review of the literature. *Int J Clin Exp Med*; 10:5525-32.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de abril de 2026.

Toxoplasmosis

Selected References:

- Cahill JB, et al. 2005. Levofloxacin secretion in breast milk: a case report. *Pharmacotherapy*, 25(1):116-118.
- Giamarellou H, et al. 1989. Pharmacokinetics of three newer quinolones in pregnant and lactating women. *The American journal of medicine*, 87(5A):49S-51S.
- Gürpınar AN, et al. 1997. The effects of a fluoroquinolone on the growth and development of infants. *The Journal of international medical research*, 25(5):302-306.
- Meaney-Delman D, et al. 2013. Prophylaxis and treatment of anthrax in pregnant women. *Obstetrics and gynecology*, 122(4):885-900.
- Padberg S, et al. 2014. Observational cohort study of pregnancy outcome after first-trimester exposure to fluoroquinolones. *Antimicrobial agents and chemotherapy*, 58(8):4392-4398.
- Shang J, et al. 2025. An Observational Study on the Pharmacokinetics of Levofloxacin in Lactating Atypical Pneumonia Patients. *Breastfeed Med*; 20(9):666-671.
- Toker SE, et al. 2021. Determination of levofloxacin by HPLC with fluorescence detection in human breast milk. *Bioanalysis*, 13(13):1063-1070.
- van den Oever HL, et al. 1998. Ciprofloxacin in preterm neonates: case report and review of the literature. *European journal of pediatrics*; 157(10):843-845.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de abril de 2026.

Toxoplasmosis

Selected References:

- Bonnot O, et al. 2001. Maternal exposure to lorazepam and anal atresia in newborns: results from a hypothesis-generating study of benzodiazepines and malformations. *J Clin Psychopharmacol*; 21(4):456-458.
- Brandlisuten RE, et al. 2017. Association of prenatal exposure to benzodiazepines and child internalizing problems: A sibling-controlled cohort study. *PLoS One*; 12(7):e0181042.
- Calderon-Margalit R, et al. 2009. Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy. *Am J Obstet Gynecol*; 201(6):579.e1-579.e8.
- Gandhi K, et al. 2023. Catatonia, Pregnancy, and Electroconvulsive Therapy (ECT). *Case Rep Psychiatry*; 7:2023:9601642.
- Iqbal MM, et al. 2002. Effects of commonly used benzodiazepines on the fetus, the neonate and the nursing infant. *Psychiatr Serv*; 53(1):39-49.
- Kargas GA et al. 1985. Perinatal mortality due to interaction of diphenhydramine and temazepam. *N Eng J Med*; 313(22):1417-1418.
- Kelly LE, et al. 2012. Neonatal Benzodiazepines Exposure during Breastfeeding. *J Pediatr*; 161(3):448-451.
- Lemmer P, et al. 2007. Quantification of lorazepam and lormetazepam in human breast milk using GC-MS in the negative chemical ionization mode. *J Anal Toxicol*; 31(4):224-226.
- Meng LC, et al. 2024. Benzodiazepine Use During Pregnancy and Risk of Miscarriage. *JAMA Psychiatry*; 81(4):366-373.
- Nishimura A, et al. 2021. Benzodiazepine Concentrations in the Breast Milk and Plasma of Nursing Mothers: Estimation of Relative Infant Dose. *Breastfeed Med*; 16(5):424-431.
- Noh Y, et al. 2022. First-trimester exposure to benzodiazepines and risk of congenital malformations in offspring: A population-based cohort study in South Korea. *PLoS Med*; 19(3):e1003945.
- Oberlander TF, et al. 2008. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. *Birth Defects Res B Dev Reprod Toxicol*; 83(1):68-76.
- Ornoy A, et al. 1998. Is benzodiazepine use during pregnancy really teratogenic? *Reprod Toxicol*; 12(5):511-515.
- Viggedal G, et al. 1993. Mental development in late infancy after prenatal exposure to benzodiazepines-prospective study. *J Child Psychol Psychiatry*; 34(3):295-305.
- Sheehy O, et al. 2019. Association Between Incident Exposure to Benzodiazepines in Early Pregnancy and Risk of Spontaneous Abortion. *JAMA Psychiatry*; 76(9):948-957.
- Tinker SC, et al. 2019. Use of benzodiazepine medications during pregnancy and potential risk for birth defects, National Birth Defects Prevention Study, 1997-2011. *Birth Defects Res Jun*, 1;111(10):613-620.
- U.S. Food and Drug Administration. 2023. Ativan label. Accessed September 2024

from https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/017794s049lbl.pdf. [Accessed April 2026]

- Whitelaw AG, et al. 1981. Effect of maternal lorazepam on the neonate. Br Med J (Clin Res Ed). 282(6270):1106-8.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de abril de 2026.